B. Riley Issues Optimistic Forecast for ARWR Earnings

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) - B. Riley raised their FY2025 earnings estimates for shares of Arrowhead Pharmaceuticals in a research report issued to clients and investors on Thursday, February 13th. B. Riley analyst M. Mamtani now forecasts that the biotechnology company will earn $1.15 per share for the year, up from their prior estimate of $1.00. B. Riley has a "Buy" rating and a $38.00 price objective on the stock. The consensus estimate for Arrowhead Pharmaceuticals' current full-year earnings is ($2.42) per share.

Several other research firms also recently weighed in on ARWR. HC Wainwright reaffirmed a "buy" rating and issued a $80.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, February 12th. Sanford C. Bernstein decreased their price target on shares of Arrowhead Pharmaceuticals from $27.00 to $24.00 and set a "market perform" rating for the company in a research note on Friday, November 29th. Piper Sandler decreased their price target on shares of Arrowhead Pharmaceuticals from $62.00 to $45.00 and set an "overweight" rating for the company in a research note on Wednesday, November 27th. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $42.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, February 11th. Finally, Chardan Capital reaffirmed a "buy" rating and issued a $60.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, February 11th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and six have given a buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus target price of $41.44.

Arrowhead Pharmaceuticals Stock Down 0.6 %

ARWR traded down $0.12 during midday trading on Monday, hitting $20.96. The company had a trading volume of 1,306,397 shares, compared to its average volume of 2,172,943. Arrowhead Pharmaceuticals has a 52 week low of $17.05 and a 52 week high of $36.72. The company has a quick ratio of 6.09, a current ratio of 6.09 and a debt-to-equity ratio of 7.27. The company has a market capitalization of $2.64 billion, a price-to-earnings ratio of -4.05 and a beta of 0.95. The stock's 50 day moving average price is $19.83 and its 200 day moving average price is $20.96.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last released its earnings results on Monday, February 10th. The biotechnology company reported ($1.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.97).

Insiders Place Their Bets

In other Arrowhead Pharmaceuticals news, insider James C. Hamilton sold 32,729 shares of the business's stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $19.82, for a total value of $648,688.78. Following the transaction, the insider now directly owns 272,122 shares in the company, valued at $5,393,458.04. The trade was a 10.74 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Adeoye Y. Olukotun sold 2,850 shares of the business's stock in a transaction dated Friday, December 27th. The shares were sold at an average price of $20.00, for a total transaction of $57,000.00. Following the completion of the transaction, the director now owns 36,740 shares in the company, valued at approximately $734,800. The trade was a 7.20 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 147,432 shares of company stock valued at $2,957,986. Corporate insiders own 4.30% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. World Investment Advisors LLC boosted its stake in Arrowhead Pharmaceuticals by 3.8% in the third quarter. World Investment Advisors LLC now owns 19,132 shares of the biotechnology company's stock valued at $371,000 after acquiring an additional 700 shares during the last quarter. Xponance Inc. lifted its stake in shares of Arrowhead Pharmaceuticals by 4.5% during the 4th quarter. Xponance Inc. now owns 17,400 shares of the biotechnology company's stock valued at $327,000 after buying an additional 744 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Arrowhead Pharmaceuticals by 21.3% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,496 shares of the biotechnology company's stock valued at $88,000 after buying an additional 788 shares in the last quarter. Summit Investment Advisors Inc. lifted its stake in shares of Arrowhead Pharmaceuticals by 2.2% during the 4th quarter. Summit Investment Advisors Inc. now owns 37,994 shares of the biotechnology company's stock valued at $714,000 after buying an additional 803 shares in the last quarter. Finally, Wellington Management Group LLP lifted its stake in shares of Arrowhead Pharmaceuticals by 1.5% during the 3rd quarter. Wellington Management Group LLP now owns 61,904 shares of the biotechnology company's stock valued at $1,199,000 after buying an additional 886 shares in the last quarter. 62.61% of the stock is currently owned by hedge funds and other institutional investors.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.